BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...as president and CBO of lung disease play Savara Inc. (NASDAQ:SVRA) to pursue other opportunities. Savara...
BioCentury | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

...which was acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in January. Pulmonary disease company Savara...
...the executive medical director of vaccine R&D at CRO Pharmaceutical Product Development LLC. BioCentury Staff Yumanity Therapeutics LLC Savara...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...at the American Diabetes Association meeting in San Francisco. Savara shares crushed after Molgradex miss Savara...
...BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar Therapeutics PureTech Health plc Resolve Therapeutics LLC Roche Savara...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...AG (SIX:SANN) Raxone idebenone Treat Leber’s hereditary optic neuropathy (LHON) South Korean MFDS action Mid-2019 Savara...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pharmaceuticals Inc. (NASDAQ:CMTA) Palovarotene Fibrodysplasia ossificans progressiva Phase III interim data; submit NDA 3Q19; 2H19 Savara...
BioCentury | Jul 27, 2018
Financial News

Savara raises $48.9M follow-on

...Pulmonary disease company Savara Inc. (NASDAQ:SVRA) raised $48.9 million on July 26 through the sale of...
...by Jefferies, Evercore, Canaccord Genuity, JMP Securities and H.C. Wainwright. Savara Inc. (NASDAQ:SVRA), Austin, Texas Alicia Parker Savara...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...in patients with dyslipidemia who have had acute coronary syndrome Ph III ODYSSEY data 1Q18 Savara...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:EXAS) 6/7/17 $245.0 $4,136.7 $4,180.7 1% Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) 6/6/17 $12.3 $67.5 $63.3 -6% Savara...
BioCentury | Jun 9, 2017
Financial News

Savara raises $43M in follow-on

...Rare respiratory disease company Savara Inc. (NASDAQ:SVRA) raised $43 million through the sale of 9 million...
...the sale of a 613,157 share overallotment on June 7. Savara Inc. (NASDAQ:SVRA), Austin, Texas Julian Zhu Savara...
BioCentury | May 26, 2017
Clinical News

Savara amends Phase III IMPALA trial of Molgradex

...Following guidance from FDA, Savara Inc. (NASDAQ:SVRA) amended the ongoing Phase II/III IMPALA trial evaluating Molgradex...
...ongoing Phase II/III IMPALA trial evaluating Molgradex to treat autoimmune pulmonary alveolar proteinosis (PAP). Specifically, Savara...
...µg inhaled Molgradex and placebo in 7-day intermittent cycles or placebo alone for 24 weeks. Savara...
Items per page:
1 - 10 of 28
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...as president and CBO of lung disease play Savara Inc. (NASDAQ:SVRA) to pursue other opportunities. Savara...
BioCentury | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

...which was acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in January. Pulmonary disease company Savara...
...the executive medical director of vaccine R&D at CRO Pharmaceutical Product Development LLC. BioCentury Staff Yumanity Therapeutics LLC Savara...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...at the American Diabetes Association meeting in San Francisco. Savara shares crushed after Molgradex miss Savara...
...BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar Therapeutics PureTech Health plc Resolve Therapeutics LLC Roche Savara...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...AG (SIX:SANN) Raxone idebenone Treat Leber’s hereditary optic neuropathy (LHON) South Korean MFDS action Mid-2019 Savara...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pharmaceuticals Inc. (NASDAQ:CMTA) Palovarotene Fibrodysplasia ossificans progressiva Phase III interim data; submit NDA 3Q19; 2H19 Savara...
BioCentury | Jul 27, 2018
Financial News

Savara raises $48.9M follow-on

...Pulmonary disease company Savara Inc. (NASDAQ:SVRA) raised $48.9 million on July 26 through the sale of...
...by Jefferies, Evercore, Canaccord Genuity, JMP Securities and H.C. Wainwright. Savara Inc. (NASDAQ:SVRA), Austin, Texas Alicia Parker Savara...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...in patients with dyslipidemia who have had acute coronary syndrome Ph III ODYSSEY data 1Q18 Savara...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:EXAS) 6/7/17 $245.0 $4,136.7 $4,180.7 1% Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) 6/6/17 $12.3 $67.5 $63.3 -6% Savara...
BioCentury | Jun 9, 2017
Financial News

Savara raises $43M in follow-on

...Rare respiratory disease company Savara Inc. (NASDAQ:SVRA) raised $43 million through the sale of 9 million...
...the sale of a 613,157 share overallotment on June 7. Savara Inc. (NASDAQ:SVRA), Austin, Texas Julian Zhu Savara...
BioCentury | May 26, 2017
Clinical News

Savara amends Phase III IMPALA trial of Molgradex

...Following guidance from FDA, Savara Inc. (NASDAQ:SVRA) amended the ongoing Phase II/III IMPALA trial evaluating Molgradex...
...ongoing Phase II/III IMPALA trial evaluating Molgradex to treat autoimmune pulmonary alveolar proteinosis (PAP). Specifically, Savara...
...µg inhaled Molgradex and placebo in 7-day intermittent cycles or placebo alone for 24 weeks. Savara...
Items per page:
1 - 10 of 28